Antibodies to elastin peptides in sera of Belgian Draught horses with chronic progressive lymphoedema
Article first published online: 5 JAN 2010
2007 EVJ Ltd
Equine Veterinary Journal
Volume 39, Issue 5, pages 418–421, September 2007
How to Cite
van BRANTEGEM, L., de COCK, H. E. V., AFFOLTER, V. K., DUCHATEAU, L., HOOGEWIJS, M. K., GOVAERE, J., FERRARO, G. L. and DUCATELLE, R. (2007), Antibodies to elastin peptides in sera of Belgian Draught horses with chronic progressive lymphoedema. Equine Veterinary Journal, 39: 418–421. doi: 10.2746/042516407X205888
- Issue published online: 5 JAN 2010
- Article first published online: 5 JAN 2010
- Paper received for publication 11.10.06; Accepted 30.01.07
- Belgian Draught horse;
- chronic progressive lymphoedema;
- anti-elastin antibodies;
Reasons for performing study: Chronic progressive lymphoedema (CPL) is a recently recognised disease of the lymphatic system characterised by lesions in the skin of the lower legs in several draught horse breeds, including the Belgian Draught hourse. Clinical signs slowly progress and result in severe disfigurement of the limbs. Ideally, supportive treatment should be started early in the disease process. However early diagnosis and monitoring progression of CPL is still a challenge.
Hypothesis: Elastin changes, characterised by morphological alterations as well as increased desmosine levels, in the skin of the distal limbs of horses affected with CPL are probably associated with a marked release of elastin degradation products, which elicit production of circulating anti-elastin antibodies (AEAbs) in the serum. An enzyme-linked immunosorbent assay (ELISA) for detection of serum AEAbs may document elastin breakdown.
Methods: An ELISA technique was used to evaluate levels of AEAbs in sera of 97 affected Belgian Draught horses that were clinically healthy except for possible skin lesions, associated with CPL in their distal limbs. The horses were divided into 5 groups according to the severity of these skin lesions: normal horses (Group 1, n = 36), horses with mild lesions (Group 2, n = 43), horses with moderate lesions (Group 3, n = 8), horses with severe lesions (Group 4, n = 10) and, as a control, healthy Warmblood horses, unaffected by the disease (Group 5, n = 83).
Results: Horses with clinical signs of CPL had significantly higher AEAb levels compared to clinically normal Belgian Draught horses and to healthy Warmblood horses. These levels correlated with severity of lesions.
Conclusions: CPL in draught horses is associated with an increase of serum AEAbs.
Potential relevance: Evaluation of serum levels of AEAbs by ELISA might be a useful diagnostic aid for CPL. Pathological degradation of elastic fibres, resulting in deficient support of the distal lymphatics, is proposed as a contributing factor for CPL in Belgian Draught horses.